GE HealthCare (GEHC)

Health Care · $38.0B market cap · SEC CIK 0001932393

Next reports on Feb 8, 2027, before the open, with analysts expecting $1.59 in earnings per share.

52-week range $58.75 to $89.77. 7% below its 52-week high and 42% above its low.

The case for GEHC

• Return on equity of 19%.
• Moves less than the market (beta 0.73).

The case against

• Expensive for its growth: 19.1× earnings, where 0% a year of growth would justify about 8×.
• Earnings per share fell 11.0%.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from GE HealthCare's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What GE HealthCare says it does

GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “our,” “us,” or “we”) is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. We have approximately 54,000 colleagues dedicated to our purpose to create a world where healthcare has no limits. Serving patients and providers for nearly 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine to help clinicians deliver more personalized, precise patient care. This is complemented by our broad service capabilities and dedication to quality and integrity with a strong operational culture, supported by our lean business system, Heartbeat. We generate revenue from the sale of medical devices, consumable products, service capabilities, and AI-enabled cloud and software solutions. We serve…

Risk factors GEHC lists in its 10-K

• We operate in highly competitive markets, competition may increase in the future, and our industry may be disrupted, requiring us to lower prices or resulting in a loss of market share
• Global geopolitical and economic instability, as well as continuing uncertainties and challenging conditions in regional economies, could adversely affect our business
• Our inability to successfully complete strategic transactions could adversely affect our business
• Any interruption in the operations of our facilities, or our suppliers’, customers’, or third-party providers’ facilities, may impair our ability to deliver products or provide services
• We may be unable to obtain, maintain, protect, or effectively enforce our IP rights
• If we are unable to attract or retain key talent and qualified employees or maintain relations with our employees, unions, and other employee representatives, it could adversely affect our business
• Increasing attention to sustainability matters, including EH&S matters, may impose additional costs on our business and expose us to new risks
• Our research and development efforts may not succeed in developing commercially successful products and technologies, which could adversely affect our business
• The FDA and equivalent global agencies tightly regulate and actively enforce the laws and regulations governing the development, authorization, and commercialization of medical devices and pharmaceutical products
• The failure to comply with the FCPA and similar anti-corruption and anti-bribery laws globally has resulted in, and could continue to result in, civil or criminal sanctions and adversely affect our business
• We are subject to antitrust and competition laws that can result in sanctions and conditions on the way we conduct our business
• We are subject to stringent privacy laws and information security regulations
• Changes in applicable tax laws and regulations, as well as adverse outcomes of ongoing and future tax audits, could adversely affect our business and our ability to use deferred tax assets
• We are exposed to risks associated with product liability claims that have been and may be brought against us or as a result of the actions or inactions of our customers or third parties that are outside of our control
• We may become involved in litigation, arbitration, and governmental proceedings, including those stemming from third-party conduct beyond our control
• Complying with our requirements under our debt instruments could adversely affect our business, results of operations, cash flows, and financial condition
• Changes in foreign currency exchange rates, equity prices, and interest rates, and unfavorable changes in economic conditions or uncertainties that affect the capital markets, could adversely affect our financial performance
• Future material impairments in the value of our long-lived assets, including goodwill, could adversely affect our business
• Certain of our directors and employees may have actual or potential conflicts of interest because of their financial interests in GE or because of their previous or continuing positions with GE
• Certain provisions in our certificate of incorporation, bylaws, and Delaware law may discourage takeovers and limit the power of our stockholders

Filings

Other Health Care companies